OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial ...

(RTTNews) - BioRestorative Therapies, Inc. (BRTX) announced that it has completed a Type B meeting with the U.S. FDA regarding a potential accelerated Biologics License Application or BLA approval ...

President Donald Trump’s 2026 State of the Union address focused on the economy, tax cuts, border security, DHS funding, Iran ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically ...

A medication used to treat high blood pressured has been recalled after a mix-up potentially resulted in some bottles containing a drug intended for those with low blood pressure. Marcan ...

The U.S. Food and Drug Administration authorized Johnson & Johnson’s Covid vaccine for emergency use in February 2021, nearly a year into the global pandemic that would go on to kill more than one ...

Sanofi’s investigational therapy rilzabrutinib has received breakthrough therapy designation from the FDA for the treatment of warm autoimmune hemolytic anemia. The designation is based on data from ...

Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland ...

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces ...

Footage from the singer’s performance in Louisiana rapidly spread across social media on Tuesday, showing the 45-year-old wearing dark sunglasses while what appeared to be a blood streamed out of his ...

Cumberland to highlight 2025 financial, international, portfolio and clinical progress NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.